Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Intracerebroventricular enzyme replacement therapy with Beta-Galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice.

Chen JC, Luu AR, Wise N, Angelis R, Agrawal V, Mangini L, Vincelette J, Handyside B, Sterling HJ, Lo MJ, Wong H, Galicia N, Pacheco G, Van Vleet J, Giaramita A, Fong S, Roy SM, Hague C, Lawrence R, Bullens S, Christianson TM, d'Azzo A, Crawford BE, Bunting S, Lebowitz JH, Yogalingam G.

J Biol Chem. 2019 Sep 3. pii: jbc.RA119.009811. doi: 10.1074/jbc.RA119.009811. [Epub ahead of print]

2.

Rabies post-exposure prophylaxis started during or after travel: A GeoSentinel analysis.

Gautret P, Angelo KM, Asgeirsson H, Lalloo DG, Shaw M, Schwartz E, Libman M, Kain KC, Piyaphanee W, Murphy H, Leder K, Vincelette J, Jensenius M, Waggoner J, Leung D, Borwein S, Blumberg L, Schlagenhauf P, Barnett ED, Hamer DH; GeoSentinel Global Surveillance Network.

PLoS Negl Trop Dis. 2018 Nov 13;12(11):e0006951. doi: 10.1371/journal.pntd.0006951. eCollection 2018 Nov.

3.

Spectrum of illness in migrants to Canada: sentinel surveillance through CanTravNet.

Boggild AK, Geduld J, Libman M, Yansouni CP, McCarthy AE, Hajek J, Ghesquiere W, Mirzanejad Y, Vincelette J, Kuhn S, Plourde PJ, Chakrabarti S, Greenaway C, Hamer DH, Kain KC.

J Travel Med. 2019 Feb 1;26(2). pii: tay117. doi: 10.1093/jtm/tay117.

PMID:
30395252
4.

Intradermal pre-exposure rabies vaccination in a Canadian travel clinic: 6-year retrospective observational study.

Kong LY, Vincelette J, Laplante G, Duchesne JA, Libman M, Barkati S.

CMAJ Open. 2018 Apr 5;6(2):E168-E175. doi: 10.9778/cmajo.20170147.

5.

Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B Mice.

Aoyagi-Scharber M, Crippen-Harmon D, Lawrence R, Vincelette J, Yogalingam G, Prill H, Yip BK, Baridon B, Vitelli C, Lee A, Gorostiza O, Adintori EG, Minto WC, Van Vleet JL, Yates B, Rigney S, Christianson TM, Tiger PMN, Lo MJ, Holtzinger J, Fitzpatrick PA, LeBowitz JH, Bullens S, Crawford BE, Bunting S.

Mol Ther Methods Clin Dev. 2017 Jun 6;6:43-53. doi: 10.1016/j.omtm.2017.05.009. eCollection 2017 Sep 15.

6.

Response to "Selection bias".

Boggild AK, Libman M, Yansouni CP, Freedman DO, Kuhn S, Plourde P, Mirzanejad Y, Hajek J, Chakrabarti S, Geduld J, McCarthy AE, Vincelette J, Ghesquiere W, Kain KC.

CMAJ. 2017 May 8;189(18):E674. doi: 10.1503/cmaj.732964. No abstract available.

7.

Surveillance report of Zika virus among Canadian travellers returning from the Americas.

Boggild AK, Geduld J, Libman M, Yansouni CP, McCarthy AE, Hajek J, Ghesquiere W, Mirzanejad Y, Vincelette J, Kuhn S, Plourde PJ, Chakrabarti S, Freedman DO, Kain KC.

CMAJ. 2017 Mar 6;189(9):E334-E340. doi: 10.1503/cmaj.161241.

8.

Malaria in travellers returning or migrating to Canada: surveillance report from CanTravNet surveillance data, 2004-2014.

Boggild AK, Geduld J, Libman M, Yansouni CP, McCarthy AE, Hajek J, Ghesquiere W, Vincelette J, Kuhn S, Freedman DO, Kain KC.

CMAJ Open. 2016 Jul 6;4(3):E352-E358. eCollection 2016 Jul-Sep.

9.

Illness in Canadian travellers and migrants from Brazil: CanTravNet surveillance data, 2013-2016.

Boggild AK, Geduld J, Libman M, Yansouni CP, McCarthy AE, Hajek J, Ghesquiere W, Vincelette J, Kuhn S, Plourde PJ, Freedman DO, Kain KC.

Can Commun Dis Rep. 2016 Aug 4;42(8):153-157. eCollection 2016 Aug 4.

10.

Netrin-1 Interrupts Amyloid-β Amplification, Increases sAβPPα in vitro and in vivo, and Improves Cognition in a Mouse Model of Alzheimer's Disease.

Spilman PR, Corset V, Gorostiza O, Poksay KS, Galvan V, Zhang J, Rao R, Peters-Libeu C, Vincelette J, McGeehan A, Dvorak-Ewell M, Beyer J, Campagna J, Bankiewicz K, Mehlen P, John V, Bredesen DE.

J Alzheimers Dis. 2016 Mar 8;52(1):223-42. doi: 10.3233/JAD-151046.

PMID:
27060954
11.

Dermatoses among returned Canadian travellers and immigrants: surveillance report based on CanTravNet data, 2009-2012.

Stevens MS, Geduld J, Libman M, Ward BJ, McCarthy AE, Vincelette J, Ghesquiere W, Hajek J, Kuhn S, Freedman DO, Kain KC, Boggild AK.

CMAJ Open. 2015 Jan 13;3(1):E119-26. doi: 10.9778/cmajo.20140082. eCollection 2015 Jan-Mar.

12.

Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB.

Kan SH, Aoyagi-Scharber M, Le SQ, Vincelette J, Ohmi K, Bullens S, Wendt DJ, Christianson TM, Tiger PM, Brown JR, Lawrence R, Yip BK, Holtzinger J, Bagri A, Crippen-Harmon D, Vondrak KN, Chen Z, Hague CM, Woloszynek JC, Cheung DS, Webster KA, Adintori EG, Lo MJ, Wong W, Fitzpatrick PA, LeBowitz JH, Crawford BE, Bunting S, Dickson PI, Neufeld EF.

Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14870-5. doi: 10.1073/pnas.1416660111. Epub 2014 Sep 29.

13.

Travel-acquired infections in Canada: CanTravNet 2011-2012.

Boggild AK, Geduld J, Libman M, Ward BJ, McCarthy A, Hajek J, Ghesquiere W, Vincelette J, Kuhn S, Freedman DO, Kain KC.

Can Commun Dis Rep. 2014 Sep 18;40(16):313-325. eCollection 2014 Sep 18.

14.

Travel-acquired infections and illnesses in Canadians: surveillance report from CanTravNet surveillance data, 2009-2011.

Boggild AK, Geduld J, Libman M, Ward BJ, McCarthy AE, Doyle PW, Ghesquiere W, Vincelette J, Kuhn S, Freedman DO, Kain KC.

Open Med. 2014 Feb 11;8(1):e20-32. eCollection 2014.

15.

Trends in human immunodeficiency virus incidence and risk behavior among injection drug users in montreal, Canada: a 16-year longitudinal study.

Bruneau J, Daniel M, Abrahamowicz M, Zang G, Lamothe F, Vincelette J.

Am J Epidemiol. 2011 May 1;173(9):1049-58. doi: 10.1093/aje/kwq479. Epub 2011 Mar 1.

16.

1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.

Anandan SK, Webb HK, Chen D, Wang YX, Aavula BR, Cases S, Cheng Y, Do ZN, Mehra U, Tran V, Vincelette J, Waszczuk J, White K, Wong KR, Zhang LN, Jones PD, Hammock BD, Patel DV, Whitcomb R, MacIntyre DE, Sabry J, Gless R.

Bioorg Med Chem Lett. 2011 Feb 1;21(3):983-8. doi: 10.1016/j.bmcl.2010.12.042. Epub 2010 Dec 13.

17.

Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension.

Zhang LN, Vincelette J, Chen D, Gless RD, Anandan SK, Rubanyi GM, Webb HK, MacIntyre DE, Wang YX.

Eur J Pharmacol. 2011 Mar 1;654(1):68-74. doi: 10.1016/j.ejphar.2010.12.016. Epub 2010 Dec 25.

PMID:
21187082
18.

First case of invasive human infection caused by Cupriavidus metallidurans.

Langevin S, Vincelette J, Bekal S, Gaudreau C.

J Clin Microbiol. 2011 Feb;49(2):744-5. doi: 10.1128/JCM.01947-10. Epub 2010 Nov 24.

19.

Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia.

Zhang LN, Vincelette J, Cheng Y, Mehra U, Chen D, Anandan SK, Gless R, Webb HK, Wang YX.

Arterioscler Thromb Vasc Biol. 2009 Sep;29(9):1265-70. doi: 10.1161/ATVBAHA.109.186064. Epub 2009 Aug 10.

PMID:
19667112
20.

Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization.

Post JM, Alexander S, Wang YX, Vincelette J, Vergona R, Kent L, Bryant J, Sullivan ME, Dole WP, Morser J, Subramanyam B.

Thromb Res. 2008;122(4):533-40. doi: 10.1016/j.thromres.2008.04.009. Epub 2008 Jun 9.

PMID:
18539312
21.

Gait analysis in a murine model of collagen-induced arthritis.

Vincelette J, Xu Y, Zhang LN, Schaefer CJ, Vergona R, Sullivan ME, Hampton TG, Wang YX.

Arthritis Res Ther. 2007;9(6):R123.

22.

Determinants of HIV seroconversion among men who have sex with men living in a low HIV incidence population in the era of highly active antiretroviral therapies.

Lavoie E, Alary M, Remis RS, Otis J, Vincelette J, Turmel B, Lavoie R, Masse BR, Le Clerc R.

Sex Transm Dis. 2008 Jan;35(1):25-9.

PMID:
17898678
23.

A novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models.

Wang YX, Vincelette J, da Cunha V, Martin-McNulty B, Mallari C, Fitch RM, Alexander S, Islam I, Buckman BO, Yuan S, Post JM, Subramanyam B, Vergona R, Sullivan ME, Dole WP, Morser J, Bryant J.

Thromb Haemost. 2007 May;97(5):847-55.

PMID:
17479197
24.

Interferon-beta attenuates angiotensin II-accelerated atherosclerosis and vascular remodeling in apolipoprotein E deficient mice.

Zhang LN, Velichko S, Vincelette J, Fitch RM, Vergona R, Sullivan ME, Croze E, Wang YX.

Atherosclerosis. 2008 Mar;197(1):204-11. Epub 2007 Apr 26.

PMID:
17466308
25.

Antiviral and myocyte protective effects of murine interferon-beta and -{alpha}2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice.

Wang YX, da Cunha V, Vincelette J, White K, Velichko S, Xu Y, Gross C, Fitch RM, Halks-Miller M, Larsen BR, Yajima T, Knowlton KU, Vergona R, Sullivan ME, Croze E.

Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H69-76. Epub 2007 Apr 13.

26.

Urokinase-type plasminogen activator deficiency (uPA-KO) prevented carotid artery ligation-induced vascular remodeling in mice.

Martin-McNulty B, Zhang L, da Cunha V, Vincelette J, Rutledge JC, Vergona R, Sullivan ME, Wang YX.

Transl Res. 2007 Feb;149(2):70-5.

PMID:
17240317
27.

A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis.

Wang YX, da Cunha V, Vincelette J, Zhao L, Nagashima M, Kawai K, Yuan S, Emayan K, Islam I, Hosoya J, Sullivan ME, Dole WP, Morser J, Buckman BO, Vergona R.

Thromb Haemost. 2007 Jan;97(1):54-61.

PMID:
17200771
28.

A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) - part I: pharmacological characterization.

Wang YX, Zhao L, Nagashima M, Vincelette J, Sukovich D, Li W, Subramanyam B, Yuan S, Emayan K, Islam I, Hrvatin P, Bryant J, Light DR, Vergona R, Morser J, Buckman BO.

Thromb Haemost. 2007 Jan;97(1):45-53.

PMID:
17200770
29.

HIV and ethnicity in Canada: is the HIV risk-taking behaviour of young foreign-born MSM similar to Canadian born MSM?

George C, Alary M, Hogg RS, Otis J, Remis RS, Mâsse B, Turmel B, Leclerc R, Lavoie R, Vincelette J, Parent R, Chan K, Martindale S, Miller ML, Craib KJ, Schechter MT.

AIDS Care. 2007 Jan;19(1):9-16.

PMID:
17129852
30.

Amplified anticoagulant activity of tissue factor-targeted thrombomodulin: in-vivo validation of a tissue factor-neutralizing antibody fused to soluble thrombomodulin.

Wang YX, Wu C, Vincelette J, Martin-McNulty B, Alexander S, Larsen B, Light DR, McLean K.

Thromb Haemost. 2006 Sep;96(3):317-24.

PMID:
16953273
31.

Angiotensin II induces histomorphologic features of unstable plaque in a murine model of accelerated atherosclerosis.

da Cunha V, Martin-McNulty B, Vincelette J, Choy DF, Li WW, Schroeder M, Mahmoudi M, Halks-Miller M, Wilson DW, Vergona R, Sullivan ME, Wang YX.

J Vasc Surg. 2006 Aug;44(2):364-71.

32.

Reduced cardiac functional reserve in apolipoprotein E knockout mice.

Vincelette J, Martin-McNulty B, Vergona R, Sullivan ME, Wang YX.

Transl Res. 2006 Jul;148(1):30-6.

PMID:
16887496
33.

Nonnegligible increasing temporal trends in unprotected anal intercourse among men who have sexual relations with other men in montreal.

George C, Alary M, Otis J, Demers E, Remis RS, Mâsse B, Lavoie R, Vincelette J, Parent R, Leclerc R, Turmel B; Omega Study Group, Omega Cohort.

J Acquir Immune Defic Syndr. 2006 Jun;42(2):207-12. Erratum in: J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):521.

PMID:
16645547
34.

Nonnegligible increasing temporal trends in unprotected anal intercourse among men who have sexual relations with other men in Montreal.

George C, Alary M, Otis J, Demers E, Mâsse B, Lavoie R, Remis RS, Turmel B, Vincelette J, Parent R, LeClerc R.

J Acquir Immune Defic Syndr. 2006 Mar;41(3):365-70. Erratum in: J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):521.

PMID:
16540939
35.

Interaction between mild hypercholesterolemia, HDL-cholesterol levels, and angiotensin II in intimal hyperplasia in mice.

da Cunha V, Martin-McNulty B, Vincelette J, Zhang L, Rutledge JC, Wilson DW, Vergona R, Sullivan ME, Wang YX.

J Lipid Res. 2006 Mar;47(3):476-83. Epub 2005 Dec 21.

36.

Inhibition of rho-kinase by hydroxyfasudil prevents vasopressin-induced myocardial ischemia in Donryu rats by attenuating coronary vasoconstriction.

Vincelette J, Pagila R, Kawai K, Ishii M, Horimizu Y, Vergona R, Sullivan ME, Morser J, Dole WP, Wang YX.

Pharmacology. 2005 Nov;75(3):145-51. Epub 2005 Sep 12.

PMID:
16158013
37.

A prognostic model for HIV seroconversion among injection drug users as a tool for stratification in clinical trials.

Boileau C, Bruneau J, Al-Nachawati H, Lamothe F, Vincelette J.

J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):489-95.

PMID:
16010174
38.

Noninvasive measurement of abdominal aortic aneurysms in intact mice by a high-frequency ultrasound imaging system.

Martin-McNulty B, Vincelette J, Vergona R, Sullivan ME, Wang YX.

Ultrasound Med Biol. 2005 Jun;31(6):745-9.

PMID:
15936490
39.

Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis.

Wang YX, Martin-McNulty B, da Cunha V, Vincelette J, Lu X, Feng Q, Halks-Miller M, Mahmoudi M, Schroeder M, Subramanyam B, Tseng JL, Deng GD, Schirm S, Johns A, Kauser K, Dole WP, Light DR.

Circulation. 2005 May 3;111(17):2219-26. Epub 2005 Apr 25.

PMID:
15851596
40.

Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice.

Wang YX, da Cunha V, Martin-McNulty B, Vincelette J, Li W, Choy DF, Halks-Miller M, Mahmoudi M, Schroeder M, Johns A, Light DR, Dole WP.

Eur J Pharmacol. 2005 Apr 11;512(2-3):215-22.

PMID:
15840407
41.

Lack of evidence of sexual transmission of hepatitis C virus in a prospective cohort study of men who have sex with men.

Alary M, Joly JR, Vincelette J, Lavoie R, Turmel B, Remis RS.

Am J Public Health. 2005 Mar;95(3):502-5.

42.

Sexual risk behaviour of Canadian participants in the first efficacy trial of a preventive HIV-1 vaccine.

Lampinen TM, Chan K, Remis RS, Merid MF, Rusch M, Vincelette J, Logue K, Popovic V, Alary M, Schechter MT, Hogg RS.

CMAJ. 2005 Feb 15;172(4):479-83.

43.

P-selectin-targeting of the fibrin selective thrombolytic Desmodus rotundus salivary plasminogen activator alpha1.

Dong N, Da Cunha V, Citkowicz A, Wu F, Vincelette J, Larsen B, Wang YX, Ruan C, Dole WP, Morser J, Wu Q, Pan J.

Thromb Haemost. 2004 Nov;92(5):956-65.

PMID:
15543321
44.

No increase in HIV incidence observed in a cohort of men who have sex with other men in Montreal.

Remis RS, Alary M, Otis J, Mâsse B, Demers E, Vincelette J, Turmel B, LeClerc R, Lavoie R, Parent R, George C; Omega Study Group.

AIDS. 2002 May 24;16(8):1183-5.

PMID:
12004279
45.

HIV-positive notification and behavior changes in Montreal injection drug users.

Brogly SB, Bruneau J, Lamothe F, Vincelette J, Franco EL.

AIDS Educ Prev. 2002 Feb;14(1):17-28.

PMID:
11900107
46.

Risk behaviours and prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae genital infections among Montreal street youth.

Haley N, Roy E, Leclerc P, Lambert G, Boivin JF, Cédras L, Vincelette J.

Int J STD AIDS. 2002 Apr;13(4):238-45.

PMID:
11886608
47.

Field evaluation of the Merlin immediate HIV-1 and -2 test for point-of-care detection of human immunodeficiency virus antibodies.

Shafran SD, Conway B, Prasad E, Greer J, Vincelette J, Ellis CE, Haase DA, Walmsley SL, Lalonde RG, Cameron DW.

Clin Infect Dis. 2002 Mar 1;34(5):658-61. Epub 2002 Jan 25.

PMID:
11823955
48.

Multicenter study of a commercial, automated polymerase chain reaction system for the rapid detection of Mycobacterium tuberculosis in respiratory specimens in routine clinical practice.

Bogard M, Vincelette J, Antinozzi R, Alonso R, Fenner T, Schirm J, Aubert D, Gaudreau C, Sala E, Ruiz-Serrano MJ, Petersen H, Oostendorp LA, Burkardt H.

Eur J Clin Microbiol Infect Dis. 2001 Oct;20(10):724-31.

PMID:
11757974
49.

Risk factors associated with HIV infection among young gay and bisexual men in Canada.

Weber AE, Chan K, George C, Hogg RS, Remis RS, Martindale S, Otis J, Miller ML, Vincelette J, Craib KJ, Mâsse B, Schechter MT, LeClerc R, Lavoie R, Turmel B, Parent R, Alary M.

J Acquir Immune Defic Syndr. 2001 Sep 1;28(1):81-8.

PMID:
11579281
50.

Risk factors for hepatitis C virus infection among street youths.

Roy E, Haley N, Leclerc P, Boivin JF, Cédras L, Vincelette J.

CMAJ. 2001 Sep 4;165(5):557-60.

Supplemental Content

Loading ...
Support Center